Targeting CK2-driven non-oncogene addiction in B-cell tumors

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Oncogene

• Publication date

  2016-11-24

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/onc.2016.86PMID 27041560
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders

  2016cited by this paper
• Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma.

  2015cited by this paper
• A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours

  2015cited by this paper
• Modulation of LSD1 phosphorylation by CK2/WIP1 regulates RNF168-dependent 53BP1 recruitment in response to DNA damage

  2015cited by this paper
• Regulation of cell proliferation by ERK and signal-dependent nuclear translocation of ERK is dependent on Tm5NM1-containing actin filaments

  2015cited by this paper
• The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL

  2015cited by this paper
• Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB

  2015cited by this paper
• Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia.

  2015cited by this paper
• Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth

  2015cited by this paper
• Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia

  2015cited by this paper
• B-cell receptor signaling in diffuse large B-cell lymphoma.

  2015cited by this paper
• Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation

  2014cited by this paper
• Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels

  2014cited by this paper
• Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.

  2014cited by this paper
• Phosphoinositide 3-kinase inhibitors in lymphoma

  2014cited by this paper
• Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia

  2014cited by this paper
• Protein kinase CK2 is required for the recruitment of 53BP1 to sites of DNA double-strand break induced by radiomimetic drugs.

  2014cited by this paper
• Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2

  2014cited by this paper
• Protein kinase CK2 and angiogenesis.

  2014cited by this paper
• PI3K and cancer: lessons, challenges and opportunities

  2014cited by this paper
• Unbalanced expression of CK2 kinase subunits is sufficient to drive epithelial-to-mesenchymal transition by Snail1 induction

  2013cited by this paper
• B-Cell Antigen Receptor Signaling in Chronic Lymphocytic Leukemia: Therapeutic Targets and Translational Opportunities

  2013cited by this paper
• CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway

  2013cited by this paper
• Protein Kinase CK2 Inhibition Down Modulates the NF-κB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells

  2013cited by this paper
• Function of Ikaros as a tumor suppressor in B cell acute lymphoblastic leukemia.

  2013cited by this paper
• Therapeutic Targeting of a Robust Non-Oncogene Addiction to PRKDC in ATM-Defective Tumors

  2013cited by this paper
• Targeting B-cell receptor signaling: changing the paradigm.

  2013cited by this paper
• Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting.

  2013cited by this paper
• Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia

  2013cited by this paper
• Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.

  2012cited by this paper
• Protein kinase CK2 localizes to sites of DNA double-strand break regulating the cellular response to DNA damage

  2012cited by this paper
• Cancer treatment according to BRCA1 and BRCA2 mutations

  2012cited by this paper
• Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFα)-induced apoptosis through SIRT1 inhibition

  2012cited by this paper
• Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways

  2012cited by this paper
• Proteasome inhibitors in multiple myeloma: 10 years later.

  2012cited by this paper
• ATM-Dependent Downregulation of USP7/HAUSP by PPM1G Activates p53 Response to DNA Damage

  2012cited by this paper
• Protein Kinase CK2 Protects Multiple Myeloma Cells from ER Stress–Induced Apoptosis and from the Cytotoxic Effect of HSP90 Inhibition through Regulation of the Unfolded Protein Response

  2012cited by this paper
• DangER: protein ovERload. Targeting protein degradation to treat myeloma

  2012cited by this paper
• Past, Present, and Future of Molecular and Cellular Oncology

  2011cited by this paper
• CK2 phosphorylation of XRCC1 facilitates dissociation from DNA and single-strand break formation during base excision repair.

  2011cited by this paper
• Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer.

  2011cited by this paper
• Regulation of epithelial to mesenchymal transition: CK2β on stage

  2011cited by this paper
• Protein kinase CK2α subunit over-expression correlates with metastatic risk in breast carcinomas: quantitative immunohistochemistry in tissue microarrays.

  2011cited by this paper
• Ikaros, CK2 kinase, and the road to leukemia

  2011cited by this paper
• A Peptide-Based Target Screen Implicates the Protein Kinase CK2 in the Global Regulation of Caspase Signaling

  2011cited by this paper
• Nuclear Extracellular Signal-Regulated Kinase 1 and 2 Translocation Is Mediated by Casein Kinase 2 and Accelerated by Autophosphorylation

  2011cited by this paper
• New therapeutic targets and drugs in non-Hodgkin's lymphoma

  2011cited by this paper
• Protein kinase CK2 accumulation in “oncophilic” cells: causes and effects

  2011cited by this paper
• A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway.

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Regulation of Ikaros function by casein kinase 2 and protein phosphatase 1.

  2011cited by this paper
• Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia.

  2010cited by this paper
• Regulation of DNA-dependent protein kinase by protein kinase CK2 in human glioblastoma cells

  2010cited by this paper
• Regulation of cell proliferation and survival: convergence of protein kinases and caspases.

  2010cited by this paper
• Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia.

  2010cited by this paper
• Emergence of protein kinase CK2 as a key target in cancer therapy

  2010cited by this paper
• CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.

  2010cited by this paper
• Addiction to protein kinase CK2: a common denominator of diverse cancer cells?

  2010cited by this paper
• Phosphorylation of serine 392 in p53 is a common and integral event during p53 induction by diverse stimuli.

  2010cited by this paper
• Ikaros Stability and Pericentromeric Localization Are Regulated by Protein Phosphatase 1*

  2009cited by this paper
• Dephosphorylation and inactivation of Akt/PKB is counteracted by protein kinase CK2 in HEK 293T cells

  2009cited by this paper
• Principles of cancer therapy: oncogene and non-oncogene addiction.

  2009cited by this paper
• Protein Kinase CK2 in Health and Disease

  2009cited by this paper
• Protein Kinase CK2 in Health and Disease

  2009cited by this paper
• Hallmarks for senescence in carcinogenesis: novel signaling players

  2009cited by this paper
• Protein Kinase CK2 in Health and Disease

  2009cited by this paper
• Pathogenic ATM mutations occur rarely in a subset of multiple myeloma patients

  2008cited by this paper
• Interferon regulatory factor 4 and 8 in B-cell development.

  2008cited by this paper
• Phosphorylation of SDT repeats in the MDC1 N terminus triggers retention of NBS1 at the DNA damage–modified chromatin

  2008cited by this paper
• IRF4 addiction in multiple myeloma

  2008cited by this paper
• Hyperactive Ras in developmental disorders and cancer

  2007cited by this paper
• Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/threonine kinase CK2

  2007cited by this paper
• Non-oncogene addiction and the stress phenotype of cancer cells.

  2007cited by this paper
• Hyperactive Ras in developmental disorders and cancer

  2007cited by this paper
• CK2 controls the recruitment of Wnt regulators to target genes in vivo.

  2006cited by this paper
• Multiple myeloma cell survival relies on high activity of protein kinase CK2.

  2006cited by this paper
• Role of protein kinase CK2 in the regulation of tumor necrosis factor-related apoptosis inducing ligand-induced apoptosis in prostate cancer cells.

  2006cited by this paper
• Protein kinase CK2 phosphorylates and upregulates Akt/PKB

  2005cited by this paper
• Casein kinase II (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced apoptosis in human colon carcinoma cell lines

  2005cited by this paper
• Role for casein kinase 2 in the regulation of HIF‐1 activity

  2005cited by this paper
• Caspase‐2 primes cancer cells for TRAIL‐mediated apoptosis by processing procaspase‐8

  2005cited by this paper
• Protein kinase CKIIa interacts with the Bcr moiety of Bcr/Abl and mediates proliferation of Bcr/Abl-expressing cells

  2004cited by this paper
• Influence of Casein Kinase II in Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Human Rhabdomyosarcoma Cells

  2004cited by this paper
• Oncogene addiction: sometimes a temporary slavery.

  2004cited by this paper
• Activation of the DNA-binding ability of latent p53 protein by protein kinase C is abolished by protein kinase CK2.

  2004cited by this paper
• CK2 Controls Multiple Protein Kinases by Phosphorylating a Kinase-Targeting Molecular Chaperone, Cdc37

  2004cited by this paper
• Protein kinase CKIIα interacts with the Bcr moiety of Bcr/Abl and mediates proliferation of Bcr/Abl-expressing cells

  2003cited by this paper
• Protein kinase CK2: structure, regulation and role in cellular decisions of life and death.

  2003cited by this paper
• p53 Serine 392 Phosphorylation Increases after UV through Induction of the Assembly of the CK2·hSPT16·SSRP1 Complex*

  2002cited by this paper
• Joining the cell survival squad: an emerging role for protein kinase CK2.

  2002cited by this paper
• The Tumor Suppressor PTEN Is Phosphorylated by the Protein Kinase CK2 at Its C Terminus

  2001cited by this paper
• A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1.

  2001cited by this paper
• Phosphorylation of the PTEN Tail Regulates Protein Stability and Function

  2000cited by this paper
• Metastasis-associated protein Mts1 (S100A4) inhibits CK2-mediated phosphorylation and self-assembly of the heavy chain of nonmuscle myosin.

  2000cited by this paper
• Mantle cell lymphoma is characterized by inactivation of the ATM gene.

  2000cited by this paper
• Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia.

  1999cited by this paper
• p53 deficiency and misexpression of protein kinase CK2α collaborate in the development of thymic lymphomas in mice

  1998cited by this paper
• Requirement for the Transcription Factor LSIRF/IRF4 for Mature B and T Lymphocyte Function

  1997cited by this paper

• Inhibiting CK2 in breast cancer: From molecular targets to drug candidates.

  2026cites this paper
• CK2: the master regulator in tumor immune-microenvironment - a crucial target in oncotherapy.

  2025cites this paper
• CK2 in the spotlight: decoding its role in hematological malignancies and therapeutic applications

  2025cites this paper
• CK2α Deletion in the Hematopoietic Compartment Shows a Mild Alteration in Terminally Differentiated Cells and the Expansion of Stem Cells

  2025cites this paper
• CK2 inhibitor, CX-4945, enhances BH3 priming and promotes apoptosis of venetoclax-resistant AML by targeting antiapoptotic proteins

  2025cites this paper
• CK2 Inhibitors Targeting Inside and Outside the Catalytic Box

  2024cites this paper
• Protein kinase CK2α is overexpressed in classical hodgkin lymphoma, regulates key signaling pathways, PD-L1 and may represent a new target for therapy

  2024cites this paper
• Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia

  2023cites this paper
• CK2β Regulates Hematopoietic Stem Cell Biology and Erythropoiesis

  2023cites this paper
• On Casein Kinase-2 (CK2) deregulation in NSCLC: an enzyme subunit-centered approach

  2023cites this paper
• Structure-guided discovery of adenosine triphosphate-competitive casein kinase 2 inhibitors.

  2023cites this paper
• Protein Kinase CK2 and Epstein–Barr Virus

  2023cites this paper
• CK2β-regulated signaling controls B cell differentiation and function

  2023cites this paper
• Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma

  2022cites this paper
• The Role of Protein Kinase CK2 in Development and Disease Progression: A Critical Review

  2022cites this paper
• Protein Kinase CK2 Regulates B Cell Development and Differentiation

  2021cites this paper
• Cell signaling pathways as molecular targets to eliminate AML stem cells.

  2021cites this paper
• Mechanistic Basis for In Vivo Therapeutic Efficacy of CK2 Inhibitor CX-4945 in Acute Myeloid Leukemia

  2021cites this paper
• Targeting Protein Kinases in Blood Cancer: Focusing on CK1α and CK2

  2021cites this paper
• Protein kinase CK2: a potential therapeutic target for diverse human diseases

  2021cites this paper
• The bioinformatics and metabolomics research on anti-hypoxic molecular mechanisms of Salidroside via regulating the PTEN mediated PI3K/Akt/NF-κB signaling pathway.

  2021cites this paper
• Role of the RNA-binding protein La in cancer pathobiology

  2020cites this paper
• New responsibilities for aged kinases in B‐lymphomas

  2019cites this paper
• Anakoinosis: Correcting Aberrant Homeostasis of Cancer Tissue—Going Beyond Apoptosis Induction

  2019cites this paper
• Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways

  2017cites this paper
• Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia

  2017cites this paper
• CK2 and PI3K are direct molecular targets of quercetin in chronic lymphocytic leukaemia

  2017cites this paper
• Approved and Experimental Small‐Molecule Oncology Kinase Inhibitor Drugs: A Mid‐2016 Overview

  2017cites this paper
• Therapeutic targeting of CK2 in acute and chronic leukemias

  2017cites this paper
• Protein kinase C downregulation induces senescence via FoxO3a inhibition in HCT116 and HEK293 cells.

  2017cites this paper
• Protéine-kinases et cancer du rein : Découverte et validation d’une nouvelle combinaison d’inhibiteurs ciblant les protéine-kinases ATM et CK2

  2016cites this paper